Open / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone
|
|
- Nicholas Morrison
- 5 years ago
- Views:
Transcription
1 This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato oncology clinical management protocols and agreed chemotherapy protocols/regimens and specifies those that are deliverable in the community. (Measures 14 7A 113, 14 7B 129, 14 6A 201, 14 7C 122, 14 7C 222). List is correct May 2016 More detailed regimen specific information is available from, R & D Alder Hey approved Trust protocols and the Alder Hey PTC Trial Protocols Diagnosis Trial Oral Chemo Protocol Title Bone Ewing sarcoma Euro Ewing 2012 International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours reecur Temozolomide International Randomised Controlled Trial of Chemotherapy for the Treatment Relapsed/refractory Ewing of Recurrent and Primary Refractory Ewing Sarcoma sarcoma CNS Low Grade Glioma LGG 2 Cooperative Multicentre Study for Children And Adolescents With Low Grade Glioma Intracranial Germ Cell SIOP CNS GCT II, Prospective trial for the diagnosis and treatment of children, adolescents and Tumour young adults with Intracranial Germ Cell Tumour. Ependymoma SIOP Ependymoma II An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma POSCU Involvement Supportive Care Level 1 G CSF administration? G CSF administration? G CSF administration at Referral to Outside CCN Surgery at Royal Orthopaediac Hospital Birmingham / Closed to Recruitment Closed to Recruitment HODGKINS dular lymphocytepredominant Hodgkin s LEUKAEMIA Acute Lymphoblastic Leukaemia (ALL) and lymphoma EuroNet PHL LP1 Prednisolone EuroNet Paediatric Hodgkin s Group. First international Inter Group Study for nodular lymphocyte predominant Hodgkin s in Children and Adolescents UKALL 2011 Methotrexate, Infant ALL Interfant 06 Methotrexate, Tioguanine, Busulfan, NEUROBLASTOMA United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and 2011 Cytarabine administration Interfant 06 Cytarabine administration High Risk Neuroblastoma HRNBL Isotretinoin High Risk Neuroblastoma Study 1 of SIOP Europe (SIOPEN) G CSF administration Relapsed / Refractory GD2 Isotretinoin Long term continuous infusion ch14.18/cho plus s.c. aldesleukin (IL 2) Neuroblastoma B CELL NHL OR B AL: HIGH Protocol Inter B Prednisolone INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS RISK PATIENTS NHL ritux 2010 WITH B CELL NHL OR B AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTS SOFT TISSUE SARCOMA n Soft Tissue Sarcoma / Malignant Rhabdoid Tumour n Metastatic Metastatic Relapsed / Refractory NRSTS 2005 STS EpSSG NRSTS 2005 A protocol for n Soft Tissue Sarcomas G CSF administration RMS 2005 Cyclophosphamide RMS 2005 A protocol for n Metastatic G CSF administration at STS RMS 2005 Information in RMS 2005 A protocol for n Metastatic. G CSF administration at STS Phase III VIT 0910 Temozolomide International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in Children and Adults with Refractory or Relapsed Closed to recruitment Ratified: vember 2011, Updated August 2012, Updated May 2013,updated May 2014
2 Clinical Management Protocols Incorporating the Agreed List of Chemotherapy Regimens (continued) n Trial Protocols Diagnosis Regimen Oral Chemo POSCU Involvement Supportive Care Level 1 Referral to Outside CCN Approval Method BONE Relapsed / Refractory Ewings Irinotecan / Temozolomide Temozolomide Approved CDEG Osteosarcoma, localised Guidelines Standard Chemotherapy Osteosarcoma plus mifamurtide mifamurtide Recommendation to Use Closed Euramos Protocol administration Metastatic Osteosarcoma Guidelines Standard Chemotherapy Osteosarcoma CDEG Approved Relapsed Osteosarcoma Ifosfamide & etoposide (as per EURAMOS) GCSF administration CDEG APPROVED CNS Atypical Teratoid Rhabdoid Tumour (ATRT) Guidelines for Management of ATRT advise EURHAB Protocol Guidelines advise EURHAB closed trial Low Grade Glioma LGG 2 Cooperative Multicentre Study for Children And Adolescents With Low Grade Glioma Closed trial High Grade Glioma High Grade Glioma Guidelines Temozolomide Relapsed/refractory High Grade Glioma PCV (Lomustine,Procarbazine and Vincristine Lomustine, Procarbazine Historical approved at chemo group approval Recurrent high grade glioma Carmustine wafers CDEG May Funding agreed alert pharmacist NWest Hub (helenpotter1@nhs.net). IFR Wales,IOM Infant High Grade Glioma HIT HGG International cooperative Phase III trial of the HIT HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, Proposed trial as guidelines. ITC/Intrventricular chemoherapy at consulatnts discretion and gliomatosis cerebri in children and adolescents < 18 years. Trial not open draft. Refractory Low Grade Glioma Bevacizumab and Irinotecan CDEG Approved. Funding via CDF. Welsh patients IFR WHSCC,IOM Refractory Low Grade Glioma vinblastine weekly Historical High Risk Medulloblastoma M1 M4 >3Yrs Use ST Jude s MB03 with risk adapted standard craniospinal RT post surgery Recommendation. and 4 courses of HD cyclophosphamide/cisplatin. High Risk Medulloblastoma M1 M4 >3Yrs POG 9031 Cisplatin Etoposide Recommendation. n Meta Medulloblastoma M0 >3yrs Standard Risk Medulloblastoma Guideline Lomustine Medulloblastoma < 3 yrs M+ OR R+ Headstart II modified. Includes infants with non desmoplastic phenotype on Temozolomide, Etoposide GCSF administration morphology Relapsed Medulloblastoma / PNET guidelines includes treatment detailed in closed trial CNS closed trial Supratentorial PNET <3yrs (including infants with non desmoplastic phenotype on morphology) Headstart II modified Temozolomide, Etoposide GCSF administration CDEG Infant Medulloblastoma Proposed Infant Medulloblastoma based on SIOP YC MB proposal, Paris 2014 Temozolamide CDEG Ratified: vember 2011, Updated August 2012, Updated May 2013,updated May 2014
3 Recurrent/progressive medulloblastoma MEMMAT metronomic and targeted anti angiogenesis therapy for children with recurrent/progressive medulloblastoma Thalidomide Etoposide Cyclophosphamide CDEG March t funded require IFR. IFR Wales,IOM Ependymoma < 3 yrs UKCCSG Infant Ependymoma Interim Guidelines Version 1 May 2006 Ependymoma > 3 yrs guidelines (Ependymoma 99) Relapsed Ependymoma Closed trial Phase II Study of Intravenous Etoposide in Patients with Relapsed Ependymoma (CNS ) Closed trial Recurrent ependymoma Carmustine wafers CDEG May t funded require IFR. IFR Wales,IOM n metastatic Pineoblastoma > 3YEARS New guidelines n metastatic Pineoblastoma in Children more than 3 years Sep 2013 Choroid Plexus Tumours CNS SIG v cycles of CarbEV:Carboplatin,Vincristine, Etoposide v 2015,. Palliative brain tumour chemotherapy Oral temozolomide Temozolomide Published Protocol Palliative brain tumour chemotherapy Oral Etoposide Etoposide NAG 8 Historical Protocol High Risk, unresponsive, progressive or relapsed High dose carboplatin and thiotepa +/ etoposide with stem cell rescue malignant brain tumours in patients up to 19 years CDEG Approved July 2012 GERM CELL Extra cranial Germ Cell tumours Interim Guidelines for the Treatment of Extracranial Germ Cell Tumours Resistant Germ cell Oxaliplatin & Gemcitabine HISTIOCYTOSIS HLH HLH 2004 Protocol, Ciclosporin Historical Protocol (Trial Closed) LCH Guidelines Langerhans Cell Histiocytosis Prednisolone Relapsed / Resistant LCH LCH S 2005 Protocol Cladrabine +/ Cytarabine Methotrexate Historical Protocol (Trial Closed) LCH progression HODGKINS Classical Hodgkin`s Treatment based on Stratum 2 of the upcoming trial protocol LCH IV (Vincristine, Prednisolone,cytarabine) EuroNet Paediatric Hodgkin s Group. Recommendations for the Diagnostics and Treatment of children and adolescents with a classical Hodgkin`s during the Interim phase between the end of the EuroNet PHL C1 Study and the start of the EuroNet PHL C2 Study Prednisolone Prednisolone new as per guideline Relapsed / Refractory Hodgkins Brentuximab CDEG Approved. Funding via CDF, Welsh patients IFR (OFF Euronet PHL C1) WHSCC/IOM Classical Hodgkin`s alternative Tx ABVD doses as per MCCN protocol LEUKAEMIA ALL Interim Guidelines for the Treatment of CYA with ALL and LBL cytarabine administration Relapsed ALL An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) follow standard arm Methotrexate, Tioguanine, Relapsed/Refractory ALL FLA(+/ G) or FLA IDA Historical Relapsed/Refractory ALL Clofarabine with cyclophosphamide, etoposide, Peg aspasaginase and CDEG Approved. Funding via CDF or check WALES/IOM dexamethasone (see closed R3) as a bridge to transplant Relapsed/Refractory T cell ALL Guidelines based on Nectar 2015 : Nelarabine and modified R3 therapy. Nelarabine funded on CDF or Check WALES/IOM Advice Ratified: vember 2011, Updated August 2012, Updated May 2013,updated May 2014
4 Philadelphia Positive ALL Philadelphia Positive ALL second line Tx Interim Recommendations for Ph+ ALL in Children utilising closed trial EsPhALL Dasatinib. Dosing in accordance with closed trial : A Phase 2 Multi Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia Imatinib, Methotrexate, cytarabine administration UK Guidance Dasatinib cytarabine administration IFR to CDF.Welsh patients IFR WHSCC/IOM Chronic Myeloid Leukaemia Guidelines for the Management of Chronic Myeloid Leukaemia in Children Imatinib UK Childhood Leukaemia Working Party Acute Promyeloctic Leukaemia APL Protocol UK V1 Management Guidelines ATRA, Methotrexate, Mercaptopurine Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Acute Myeloid Leukaemia in Down's Syndrome Treatment Guidelines for AML or High Risk Myelodysplastic Syndrome Jan 2016 ML DS 2007 A Treatment Recommendation for Acute Myeloid Leukaemia of Down syndrome for adoption by the Children s Cancer and Leukaemia Group () and the United Kingdom and Republic Of Ireland Childhood Leukaemia Clinicians Network Leukaemia Subgroup NCRI Children s Cancer and Leukaemia Clinical Studies Group WEBSITE Guideline Chronic Myeloproliferative Disorders Treatment Recommendations for Chronic Myeloproliferative Disorders in Aspirin, Hydroxycarbamide, UK Childhood Leukaemia Working Party Childhood Anegrilide Relapsed AML Relapsed non APL AML 2010 Historical. Daunoxome requires IFR. Relapsed/Refractory AML FLA(+/ G) or FLA IDA Historical Relapsed/Refractory AML Clofarabine with chemotherapy as a bridge to transplant CDEG Approved. Funding via CDF or WHSCC JMML Leukaemias with ABL Translocations in Patients with Imatinib RESISTANCE OR INTOLERANCE APLASTIC ANAEMIA IV cytarabine, ITC (cytarabine, hydrocortisone), progressing Mercaptopurine to AML type treatment and BMT if required. Dasatinib Dasatinib CDEG Approved Relapsed/Refractory ALL. IFR required. Aplastic Anaemia in Childhood Treatment Aplastic Anaemia in Childhood Treatment Recommendations Version 3.1 4th July 2013 LIVER Hepatoblastoma Standard Risk Cisplatin monotherapy arm of the SIOPEL 3 and 6 Hepatoblastoma High Risk Draft Guidance for treating HR HB: eg superplado arm of the SIOPEL 3. SIOPEL Group Consider SIOPEL IV patient > 8 years Metastatic SIOPEL 4 SIOPEL Group. NEUROBLASTOMA Relapsed/Progressive High Risk Neuroblastoma NEUROBLASTOMA SPECIAL INTEREST GROUP Options for the Treatment of Patients with Relapsed/Progressive High Risk Neuroblastoma March 15 Relapsed Neuroblastoma In house metronomic chemotherapy Cis retinoic acid, etoposide, celecoxib, temozolomide, Imatinib solid tumour Ratified: vember 2011, Updated August 2012, Updated May 2013,updated May 2014
5 Low and Intermediate Risk Neuroblastoma Guidelines Treatment of Patients with Low/Intermediate Risk Neuroblastoma Jan 2015 Burkitt/Burkitt like and B large cell n Hodgkin Interim Guidelines for the Management of Burkitt/Burkitt like and B large cell n Hodgkin Prednisolone T cell and B cell lymphoblastic lymphoma Interim Guidelines for treatment of Children and Young Persons with Acute Prednisolone, dexamethasone, Cytarabine administration co to check with JH IS THIS EuroLB Lymphoblastic Leukaemia and Lymphoblastic mercaptopurine Anaplastic Large Cell Guidelines Recommending ALCL 99 Relapsed Anaplastic Large Cell NHL ALCL Relapse Protocol Closed Trial Lomustine Recommendation RARE TUMOURS (Miscellaneous) Intracranial Meningioma Guidelines for the Management of Intracranial Meningioma Melanotic Neuroectodermal Tumour of Infancy Nasopharyngeal Carcinoma Adrenocortical Tumours (ACT) & Adrenocortical Carcinoma (ACC) Pancreatic Tumours Endocrine Tumours Craniopharyngioma / Adrenocortical Tumours / Differentiated Thyroid Carcinoma / Phaeochromocytoma / MTC / Hyperparathyroidism & Pituitary Tumours (MEN) Kaposiform Haemangioendothelioma & Kasabach Merritt Syndrome RENAL Guidelines for the Management of Melanotic Neuroectodermal Tumour of Infancy Guidelines for the Investigation and Management of Nasopharyngeal Carcinoma Guidelines on the Management of Adrenocortical Tumours ACT and Mitotane Adrenocortical Carcinoma ACT Guidelines for the Investigation and Management of Pancreatic Tumours Guidelines Paediatric Endocrine Tumour Guidelines GCSF administration Guidelines Sirolimus Sirolimus Wilms Tumour SIOP Wilms UK Protocol SIOP Follow Closed Trial Relapsed / Refractory Wilms and Clear Cell Sarcoma of Kidney RETIBLASTOMA Intraoccular Retinoblastoma I Chemotherapy Unilateral Retinoblastoma following primary enucleation SOFT TISSUE SARCOMA Relapsed Refractory Wilms Tumour and CCSK UKW R Protocol Follow Closed Trial Guidelines for the Management of Children with Intraocular Retinoblastoma I Chemotherapy Guidelines for the Management of Children with Advanced unilateral Retinoblastoma following primary enucleation Metastatic Metastatic (RMS) Treatment Recommendations Cyclophosphamide Relapsed Chemotherapy recommendations for relapsed RMS EpSSG Phase II committee EpSSG Phase II committee RELAPSED and REFRACTORY TUMOURS Generic palliative chemotherapy solids and brain tumours Relapsed and Refractory Extra Cranial Solid Tumours Relapsed and Refractory Extra Cranial Solid Tumours and CNS Tumours STEM CELL TRANSPLANT oral etoposide Etoposide Gemcitabine and docetaxel temozolomide and irinotecan +/ Vincristine (VIT) Temozolomide no no Published Protocol Ratified: vember 2011, Updated August 2012, Updated May 2013,updated May 2014
An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato-oncology clinical management protocols and agreed chemotherapy
More information1. Background & Scope 3
Birmingham Children s Hospital Primary treatment centre (PTC) list of protocols and guidelines which contain approved cytotoxic chemotherapy regimens Updated 9 th June 2016 (Jason Patel) Contents 1. Background
More informationShared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)
Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group) January 2013 The NCIN is a UK-wide initiative, working to drive improvements in standards of cancer care and clinical outcomes by improving
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationDiagnosis Place of delivery Proforma
STCYPCNG List of chemotherapy regimens Day Localised Unresectable neuroblastoma (CCLG guidelines) Carbo-Etoposide Etoposide CADO Doxorubin, Vincristine Irinotecan, Irinotecan-TMZ temozolomide Localised
More informationCLIC Sargent Eligibility Criteria
1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd
More informationPaediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies. Open. In Development. In Development. Open. Open.
Paediatric Cancer Brain LGG2: Cooperative multicenter study for children and adolescents with Low Grade Glioma GD2: A Phase I/II dose schdule finding study of CH14.18/CHO continuous infusion combined wugt
More informationASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
More informationPEDIATRIC. BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a COMPANION STUDIES
PEDIATRIC BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients. https://clinicaltrials.gov/ct2/show/nct00392327?term=0332&rank=6
More informationCURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
More informationPaediatric Cancer. Brain. Germ Cell. Embryonic Tumour. Haematology Malignancies
Paediatric Cancer Brain SIOP Ependymoma II; An International Multi Centre Clinical Program for the ependymoma@trials.bham.ac.uk diagnosis and treatment of children, adolescents and young adults with Ependymoma
More informationOVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
More informationMethoden / Methods inc. ICCC-3 105
Methoden / Methods inc. ICCC-3 105 Internationale Klassifikation der Krebserkrankungen bei Kindern (ICCC-3) Zuordnung von ICD-O-3-Codes für Morphologie und Topographie zu diagnostischen Kategorien International
More informationPeninsula and Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Children s Cancer Network Group. Clinical Guidelines.
Peninsula and Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Children s Cancer June 2018 Revision due: April 2020 Page 1 of 32 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT. PLEASE
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationPeninsula and Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Children s Cancer Network Group. Clinical Guidelines.
Peninsula and Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Children s Cancer April 2019 Revision due: April 2021 Page 1 of 38 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT. PLEASE
More informationClinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL)
Clinical Guidelines for Lymphoid Diseases Acute Lymphoblastic Leukaemia (ALL) Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-107 8 Dr Helen Barker
More informationProceedings of Congress
HK J Paediatr (new series) 2012;17:123-129 Proceedings of Congress 2011 Annual Scientific Meeting: Hong Kong Paediatric Haematology and Oncology Study Group 26 March 2011 Acute Lymphoblastic Leukaemia
More informationStandard Regimens for Haematology
Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m
More informationChildhood cancer registration in England: 2015 to 2016
Childhood cancer registration in England: 2015 to 2016 Report on behalf of the Children, Teenagers and Young Adults Site Specific Clinical Reference Group, National Cancer Registration and Analysis Service
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationTUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)
Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking
More informationTUESDAY, 18th OCTOBER, 2016 / DAY -2
Legend: Keynote Educational PODC Symposium Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite Symposium SIOPe GA SIOP ABM Late
More informationClinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation December 2012 Reference : NHSCB/B4/a/1 NHS Commissioning Board Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationNational Registry of Childhood Tumours Progress Report, 2010
National Registry of Childhood Tumours Progress Report, 21 The material which follows constitutes the first of a series of reports produced by the National Registry of Childhood Tumours (NRCT) for the
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationAlexander Fosså, M.D. PhD.
Alexander Fosså, M.D. PhD. Current position: Senior Consultant, Department of Medical Oncology Oslo University Hospital Focus of work: - Malignant lymphoma - Chemotherapy, immunotherapy, radiotherapy -
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationDisturbances of female reproductive system in survivors of childhood cancer
Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the
More informationPediatric Oncology. Vlad Radulescu, MD
Pediatric Oncology Vlad Radulescu, MD Objectives Review the epidemiology of childhood cancer Discuss the presenting signs and symptoms, general treatment principles and overall prognosis of the most common
More informationSCIENTIFIC TIMETABLE SIOP 2015
SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00
More informationH&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
More informationFrequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository ( ) for cancer in Teenagers and Young Adults
Frequency of non specific morphology codes (ICD O M) within the National Cancer Data Repository (2007 09) for cancer in Teenagers and Young Adults (TYA) CTYA SSCRG Data quality report on the frequency
More informationPediatric cancer. Kleebsabai Sanpakit, MD. Hemato/Oncology division, Department of Pediatrics Faculty of Medicine Siriraj hospital
Pediatric cancer เทคน คการให รห สโรค Siriraj Cancer ICD-O Registry ฉบ บม ออาช พ Kleebsabai Sanpakit, MD. Hemato/Oncology division, Department of Pediatrics Faculty of Medicine Siriraj hospital Different
More informationThe medical team consists of 2 Hemato-Oncologists pediatrician and 6 Hematologists pediatricians.
Dr. Robert Reid Cabral Children s Hospital Dominican Republic Brief Description of the Hematology-Oncology Service Palliative Care Pilot Program and Metronomic Therapy Dr. Robert Reid Cabral Children's
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationIntroduction to Pediatric Neoplasms
Introduction to Pediatric Neoplasms F C D S E D U C A T I O N A L W E B C A S T S E R I E S S T E V E N P E A C E, B S, C T R / M A Y R A E S P I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More information1/15/2013. Introduction to Pediatric Neoplasms. Program Outline. Introduction
Introduction to Pediatric Neoplasms F C D S E D U C A TI O N A L WE B C A S T S E R I E S ST E VE N P E A C E, B S, C T R / MA Y R A E SP I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
More informationWorking Formulary January 2013 Oncology Chemotherapy Regimens
Working Formulary January 2013 Oncology Chemotherapy Regimens In the currently changing commissioning landscape, this document is intended to represent the up to date list of non clinical trial chemotherapy
More informationCoversheet for Network Site Specific Group Agreed Documentation. Diagnosis and Staging Protocol
Coversheet for Network Site Specific Group Agreed Documentation Document Title Diagnosis and Staging Protocol Document Date July 2010 Consultation Process Consultation was by the West Midlands Children
More informationChildhood Cancer Statistics, England Annual report 2018
Childhood Cancer Statistics, England Annual report 2018 Report on behalf of the Children, Teenagers and Young Adults Expert Advisory Group, National Cancer Registration and Analysis Service 1 About Public
More informationTable 7: PBTC Protocols [ ] Protocol Title Strata Status Neuroimaging Objective/Test
Table 7: PBTC Protocols [001 009] Protocol Title Strata Status Neuroimaging Objective/Test PBTC-001 PBTC-002 PBTC-003 PBTC-004 PBTC-005 PBTC-006 PBTC-007 PBTC-009 A Pilot of Systemic and Intrathecal Chemotherapy
More informationAn introduction to the Essential Medicines concept: balancing innovation with public health priorities
An introduction to the Essential Medicines concept: balancing innovation with public health priorities WHO HQ, Geneva 11 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the Selection and
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationBrain Tumors in Children
Brain Tumors in Children Michael A. Grotzer University Children s Hospital of Zurich, Switzerland Incidence of Childhood Cancer CNS Tumors Acute lymphoblastic Leukemia Neuroblastoma Non-Hodgkin Lymphoma
More informationWorld Health Organization: Essential Medicines and Devices for Cancer:
World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationRadiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
More informationPediatric Cancer in Idaho,
Pediatric Cancer in Idaho, 1996-2006 Although relatively rare in comparison with cancer in older adults, cancer is the second leading cause of death in persons aged 1-14 years. The epidemiology of cancer
More informationTreatment of Paediatric Cancers in Hong Kong: An Interim Report
HK J Paediatr (new series) 2001;6:110-115 in Hong Kong: An Interim Report CK LI, GCF CHAN, KW CHIK, SY HA, YL LAU, ACW LEE, CY LEE, CK LI, SC LING, CW LUK, MMK SHING, HL YUEN, PMP YUEN Abstract Key words
More informationPattern of deaths in the year following diagnosis in cancer patients aged years in England. Children and Young Adults CRG
Pattern of deaths in the year following diagnosis in cancer patients aged 15-24 years in England Children and Young Adults CRG Pattern of deaths in the year following diagnosis in cancer patients aged
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationContacts. Catherine Aftandilian, MD, MS Gary Dahl, MD Norman Lacayo, MD. Allison Pribnow, MD Sheri Spunt, MD, MBA
and Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation Contacts General Inquiries: Oncology Christina Baggott, RN, PhD General Inquiries: Hematology Elaine Macasiray, RN AML, ALL Catherine
More informationRegence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER
Regence Medicare Advantage Policy Manual Policy ID: M-TRA45 Stem Cell / Bone Marrow Transplants Published: 10/01/2018 Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationNational Cancer Drugs Fund List
National Cancer s Fund List (Including list of NICE approved and baseline funded drugs/indications from 1st April 2016 with criteria for use) ver1.95 20-Jul-18 NHS England INFORMATION READER BOX Directorate
More informationSubspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident
Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident Residents: Pediatric residents at the PL3 level Prerequisites: Successful completion or waiver
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationOPCS Classification of Interventions and Procedures Version 4.6 (April 2011)
Chemotherapy Regimens Clinical Coding Guidance OPCS-4.6 Version 1.0 Programme Sub Programme Data Standards & Products Clinical Classifications Document Record ID Key NPFIT-SHR-SHI-0318.01 Programme Director
More informationSOLID TUMOURS IN CHILDHOOD
SOLID TUMOURS IN CHILDHOOD Fareed Omar Paediatric Oncology Steve Biko Academic hospital Introduction 1 Introduction Lymphomas and Leukemias make up about 40% of all childhood Cancers (Systemic cancers)
More informationProtocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249
Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin
More informationTreatment Algorithm: Multiple Myeloma
Treatment Algithm: Multiple Myeloma This algithm applies to the majity of patients but may not be applicable to every patient. Patients should be enrolled in clinical trials if possible at all stages,
More informationAdditional information to support. The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines
Additional information to support The National Patient Safety Agency s Rapid Response Report Risks of incorrect dosing of oral anti-cancer medicines Reference: NPSA/2008/RRR001 - issued on 22 January 2008
More informationRESEARCH COMMUNICATION. Childhood Cancer Incidence and Survival , Thailand: Study from the Thai Pediatric Oncology Group
Childhood Cancer Incidence and Survival 2003-2005, Thailand RESEARCH COMMUNICATION Childhood Cancer Incidence and Survival 2003-2005, Thailand: Study from the Thai Pediatric Oncology Group Surapon Wiangnon
More informationSOUTH THAMES CHILDREN S AND YOUNG PEOPLE S CANCER NETWORK GROUP CLINICAL MANAGEMENT PROTOCOLS
SOUTH THAMES CHILDREN S AND YOUNG PEOPLE S CANCER NETWORK GROUP CLINICAL MANAGEMENT PROTOCOLS Contents Leukaemias Lymphoma amd Reticulo-Endothelial Malignancy Central Nervous System Tumours Sympathetic
More informationThe International Classification of Diseases for Oncology (ICD-O) is
1425 COMMENTARY Classification Schemes for Tumors Diagnosed in Adolescents and Young Adults Ronald D. Barr, M.B., Ch.B., M.D. 1 3 Eric J. Holowaty, M.D., M.Sc. 4 Jillian M. Birch, B.Sc., M.Sc., Ph.D. 5
More informationAcute Lymphoblastic Leukaemia Guidelines
Acute Lymphoblastic Leukaemia Guidelines Approved by Pathway Board for Haematological Malignancies Coordinating author: Adele Fielding, Royal Free London NHS Trust Date of issue: 12.03.2015 Version number:
More informationCCSS Concept Proposal Working Group: Biostatistics and Epidemiology
Draft date: June 26, 2010 CCSS Concept Proposal Working Group: Biostatistics and Epidemiology Title: Conditional Survival in Pediatric Malignancies: A Comparison of CCSS and SEER Data Proposed Investigators:
More informationPITFALLS AND TRAPS IN THE DIAGNOSIS AND STAGING OF RENAL TUMOURS OF CHILDHOOD. Gordan M. Vujanić Cardiff, U.K.
PITFALLS AND TRAPS IN THE DIAGNOSIS AND STAGING OF RENAL TUMOURS OF CHILDHOOD Gordan M. Vujanić Cardiff, U.K. RENAL TUMOURS OF CHILDHOOD - CLASSIFICATION (2016) Nephroblastic tumours Mesenchymal tumours
More informationProtocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy
Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal
More informationPEDIATRIC CANCER IN IDAHO
PEDIATRIC CANCER IN IDAHO 2001-2010 May 2013 A Publication of the ACKNOWLEDGMENTS The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare,
More informationPEDIATRIC CANCER IN IDAHO
PEDIATRIC CANCER IN IDAHO 1999-2008 May 2011 A Publication of the ACKNOWLEDGMENTS The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare,
More informationSignificant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions
Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Susannah E. Koontz, PharmD, BCOP Clinical Pharmacy & Education Consultant Pediatric Hematology/Oncology and
More informationThe IMI2 ITCC-P4 Paediatric Preclinical Proof-of-Concept Platform ACCELERATE 2018 Grant Agreement No ITCC-P4
The IMI2 ITCC-P4 Paediatric Preclinical Proof-of-Concept Platform ACCELERATE 2018 Grant Agreement No 116064 ITCC-P4 Louis Stancato, Eli Lilly and Company On behalf of the ITCC-P4 Leadership Team Gilles
More informationLessons from treatment of pediatric sarcomas at difficult sites. Dr. Andrea Ferrari Pediatric Oncology Unit Istituto Nazionale Tumori, Milan, Italy
Lessons from treatment of pediatric sarcomas at difficult sites Dr. ndrea Ferrari Pediatric Oncology Unit stituto Nazionale Tumori, Milan, taly Disclosure slide have no potential conflicts of interest
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More information13-24 year olds with cancer in England Incidence, mortality and survival
13-24 year olds with cancer in England Incidence, mortality and survival National Cancer Registration and Analysis Service in collaboration with Teenage Cancer Trust About Public Health England Public
More informationThe adolescents and young adults population (AYA) has
ORIGINAL ARTICLE Survival Analysis After Diagnosis With Malignancy of Egyptian Adolescent Patients: A Single-center Experience Azza A. G. Tantawy, MD,* Nayera H. K. El Sherif, MD,* Fatma S. E. Ebeid, MD,*
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationBackground. Paediatric cancer. Leukaemia
66 9. Paediatric cancer Background Radiotherapy (RT) is an important modality of therapy in the local control of paediatric malignancies and the majority of paediatric tumours are radiosensitive. However,
More informationMedical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
More informationCase 1. Maysa Al-Hussaini MD FRCPath
Case 1 Maysa Al-Hussaini MD FRCPath MAYSA King AL-HUSSAINI Hussein Cancer MD Center MRCPATH KING HUSSEIN Amman CANCER Jordan CENTER Clinical history 4 year old boy History of frontal headache, sleepiness.
More informationSOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014
SOUTH THAMES CHILDREN S CANCER NETWORK GROUP REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014 Contents 1. Leukaemia Referral, Diagnostic and Staging Guidelines 2. Lymphoma Referral,
More informationSurvival in Teenagers and Young. Adults with Cancer in the UK
Survival in Teenagers and Young Adults with Cancer in the UK Survival in Teenagers and Young Adults (TYA) with Cancer in the UK A comparative report comparing TYA cancer survival with that of children
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cns_embryonal_tumors
More informationTreatment of Recurrent. Central Nervous System. Primitive Neuroectodermal Tumours (PNETs) in Children and Young People. Version 1.
Treatment of Recurrent Central Nervous System Primitive Neuroectodermal Tumours (PNETs) in Children and Young People Version 1.0 September 2011 Barry Pizer on behalf of the CCLG CNS Interest Group Guidance
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationN. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013
N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013 Bladder HABIO Haematuria Biomarker Study Bowel Cancer NSCCG National Study Of Colorectal Cancer Genetics
More informationAn Overview. Paediatric Oncology. In Malawi
An Overview of Paediatric Oncology In Malawi 15.6 % of all cancers are attributable to infections 21% -100,000/yr in Africa; 9% - 375,000/yr in West Pidani et al 1990 IN AFRICA EARLY ACQUISITION OF VIRUSES
More informationCancer Incidence in Belgium
Cancer Incidence in Belgium 2010 Special issue Cancer in Children and Adolescents Belgian Cancer Registry Cancer Incidence in Belgium 2010 Special issue Cancer in Children and Adolescents Belgian Cancer
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationChemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors
Chemotherapy for Childhood and Primitive Neuroectodermal Tumors ROGER J. PACKER, a JONATHAN L. FINLAY b a Department of Neurology, Children s National Medical Center, Washington DC, USA; b Departments
More information